INTRODUCTION
Mild hemophilia is an X-linked bleeding disorder defined by factor VIII or IX (FVIII/FIX) levels between 5 and 40 U/dL. Until recently, the disorder has received relative little attention because of its purported low morbidity rate, resulting in an apparently uncomplicated quality and duration of life, in absence of virally induced comorbidities [1] [2] [3] . In a recent cohort study, 23 % of patients with mild hemophilia were HCV positive, a proportion substantially lower than in severe patients 3, 4 .
In patients with mild hemophilia A (MHA) excessive bleeding usually occurs after minor trauma, dental procedures, or surgery. This is unlike patients with severe deficiency (FVIII < 1 U/dL), who frequently bleed spontaneously without preceding trauma 2 . Diagnosis of MHA usually occurs later in life and a significant proportion of cases may be diagnosed during subsequent family investigation 3, 5 .
However, because of delayed presentation of bleeding, sometimes these patients could be firstly seen by physicians who are not used to interpreting symptoms of bleeding 6 . Thus these symptoms could be more dramatic at time of initial assessment, with the risk of intensive treatment with FVIII concentrates, potentially increasing the risk for inhibitor development (see below).
This review will focus on the emerging issue of inhibitor development in MHA, its molecular and clinical predictors, preventive strategies and treatment 3, 4 . and the patient's endogenous FVIII , reflecting the specificity of the T-cell epitope 11, 12 . Recently it has been suggested that the risk of inhibitor formation associated with FVIII missense mutations is significantly higher when amino acid substitution belongs to another physicochemical class than the original residue 13 . However, the recent description of an association between an intronic mutation (IVS10-18 G>A) and inhibitor occurrence after intensive replacement treatment and more than 90 ED again suggests that the pathogenesis may be heterogeneous 14 . In conclusion, genetic testing at diagnosis would be useful to identify subjects with high risk mutations before planning F VIII replacement therapy.
INHIBITOR RISK IN MILD HEMOPHILIA A: NOT SO EARLY, NOT SO LOW
Inhibitors may appear especially after a period of intensive treatment or continuous infusion with FVIII concentrate and no association with a particular concentrate is evident [15] [16] [17] . 20, 21 .
Data on immune tolerance induction in patients with MHA and inhibitors are mostly anecdotal and heterogeneous so that a definite conclusion and guidance on the best regimen is not feasible.
Immunomodulatory drugs such as corticosteroids, cyclophosphamide, anti-CD20 monoclonal antibody rituximab have also been used 17, 19, 22 as well as avoidance of re-exposure to exogenous FVIII using desmopressin and bypassing agents to treat bleeding episodes 19 . Immune tolerance induction could be more effective than no specific treatment or immunomodulating drugs in preventing risk of anamnesis of the inhibitor after re-exposure to factor VIII 7 . The INSIGHT study showed that in half of the nonsevere HA patients the inhibitor disappeared without eradication treatment 19 . However, this does not imply sustained success, as the inhibitor may return after the patient is treated again with FVIII concentrates (anamnestic response). Both high titer and low titer inhibitor patients seemed to benefit from eradication treatment, but in patients with low titer inhibitors sustained success without eradication was also likely 19 .
HOW TO REDUCE THE RISK OF INHIBITOR IN MILD HEMOPHILIA A
Desmopressin represents the therapeutic option of first choice in MHA since it is cheap, safe and carries no risk of blood-borne virus transmission 23, 24 . Desmopressin (typically at 0.3 μ g/kg body weight)
is usually administered intravenously diluted in 50-100 mL saline infused over 20-30 min or subcutaneously, when concentrated formulation is available, which could be more convenient for home-
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treatment. The drug is also available as intranasal spray administration, which can however result in variable adsorption with less FVIII/VWF increase. Desmopressin induces a 2-5 fold increase of plasma FVIII and VWF levels after administration 23, 24 . It has been suggested that FVIII levels of at least > 30 U/dL are adequate for the treatment of spontaneous or post-traumatic bleeding, while FVIII levels > 50 U/dL are required to cover major surgery 23, 24 , though in the latter case levels of 80-100 U/dL should be achieved. However, no randomized or controlled clinical trial is available and treatment modality remains almost empirical. Although FVIII increase occurs in most cases, only 50-60 % of patients achieve FVIII levels > 50 U/dL 3,24-27 . The peak post-desmopressin depends in part on the patient's basal FVIII level 25, 26 and age. Young children often have markedly lower responses to desmopressin than adults, but they may become responsive at an older age [28] [29] [30] . The FVIII half-life, typically around 6-8 h, is positively associated with basal and peak VWF antigen levels and patient age 25 . Some mutations are consistently associated with favourable responses, and in particular several of those at risk of inhibitor (Table 1) , while promoter, splicing or intronic mutations respond poorly and some missense mutations show a reduced FVIII survival 3,25-28 ( Figure 1) . Although there is a certain consistency of the response within the same mutation, the response to desmopressin is somehow heterogeneous [25] [26] [27] [28] 30 . Therefore, the individual response should always be assessed by a test-infusion of desmopressin with FVIII measured at least 1 and 4 hours after its administration to ascertain the pattern of response and the rate of clearance. In von Willebrand disease rapid clearance of VWF after desmopressin is an important pathophysiological mechanism associated with some mutations (e.g., R1205H), especially located in D3 domain of VWF 31 , while there is scarce published evidence for possible increased clearance of FVIII after desmopressin in MHA. Nevertheless, since in a few patients there is evidence of fast FVIII clearance 25 ( Figure 1) , it seems advisable to test at least after 4 hours after. Tachyphylaxis (i.e. a reduced response upon repeated administrations) should be considered when using desmopressin at closely-spaced intervals during surgical procedures 24, 32 .
Desmopressin should be used whenever possible in the treatment of MHA, not only to reduce the cost of treatment, but also to minimize the exposure to exogenous FVIII and thereby reducing the risk of inhibitor development. For major surgery a combined use of desmopressin and FVIII concentrates could
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From be suggested to reduce exposure to FVIII concentrates and the associated risk of inhibitors in patients with high-risk mutations. Most frequent mutations associated with inhibitor risk respond well to desmopressin but published information are scanty for other more rare mutations ( Table 1 ).
The frequency of desmopressin administrations should be guided by monitoring FVIII levels at 12-hour interval during surgery. As an adjunct to desmopressin antifibrinolytics can be used as a concomitant treatment, especially for mucosal bleeding.
Hyponatremia and volume overload due to the antidiuretic effect of DDAVP occur rarely, but small children who have received closely repeated infusions are particularly at risk 33 . To avoid this complication, fluid intake should be limited during DDAVP treatment. Finally, this drug should be used cautiously in patients with uncontrolled hypertension, recent myocardial infarction or stroke, or suffering from angina, which have been reported to occur following its use 34, 35 . FVIII concentrates remain the mainstay of treatment in patients unresponsive to desmopressin, if sustained long-term correction of FVIII levels is mandatory or when contraindications to the use of desmopressin are present.
CONCLUSIONS
There is a growing interest in MH. 
